Key HighlightsDataMEDS AI (MEDS) shares climbed 87.20% to $1.62 following the finalization of its Helomics Corp. purchase from Axe Compute (AGPU)The transaction totaled $1.5 million, executed via common stock and an acquisition note without assuming external debtDataMEDS obtained Helomics’ CLIA/CAP-certified laboratory facility, complete equipment inventory, Predictive Oncology CRO operations, plus $1.5 million cashThe strategic move positions DataMEDS within the expansive $40 billion U.S. oncology diagnostics and therapeutics sectorMEDS maintains approximately $5 million market capitalization and experienced a 97.64% decline throughout the previous yearShares of DataMEDS AI (NASDAQ: MEDS) surged 87.20% to finish at $1.62 during Tuesday’s trading session after announcing the successful completion of its Helomics Corporation acquisition from Axe Compute Inc. (NASDAQ: AGPU). Pre-market activity showed gains reaching 66% before momentum accelerated during standard market hours.DataMEDS AI, Inc., MEDSThe purchase price reached $1.5 million, financed entirely through equity issuance and an acquisition note structure. DataMEDS strategically avoided assuming any external liabilities during the transaction.Through the agreement, DataMEDS obtained Helomics’ fully certified CLIA/CAP clinical laboratory facilities, complete ownership of laboratory assets, the Predictive Oncology contract research organization’s central lab operations, alongside $1.5 million in liquid assets.Pittsburgh-headquartered Helomics leverages artificial intelligence technology to examine real-world tumor datasets. The laboratory specializes in supporting pharmaceutical development initiatives and clinical treatment strategies through functional precision medicine methodologies.This strategic acquisition provides DataMEDS immediate access to the substantial U.S. cancer diagnostics and therapeutics sector, currently valued at approximately $40 billion.Diversification Beyond Current Service LinesGerald Commissiong, serving as Interim Co-CEO of DataMEDS, emphasized that the transaction establishes the company’s presence in oncology services, particularly targeting underserved patient populations in remote communities. He outlined DataMEDS’ strategy to broaden its portfolio beyond managing GLP-1 agonist complications and Long COVID treatment into comprehensive cancer detection and therapy.Following integration under DataMEDS’ management, Helomics will extend operations beyond its current tumor molecular profiling and chemosensitivity analysis capabilities. The expansion roadmap encompasses comprehensive cancer screening programs, conventional CLIA laboratory offerings, and nutritional therapy solutions for oncology patients.Axe Compute’s CEO Chris Miglino highlighted that the transaction framework preserves his organization’s equity interest in Helomics moving forward. Axe Compute will redirect its resources toward expanding its primary AI infrastructure operations.Helomics represented the final operational asset from Axe Compute’s former corporate structure as Predictive Oncology Inc., preceding the company’s transformation completed in December 2025.Financial MetricsDataMEDS currently maintains a market capitalization near $5 million. The stock’s 52-week trading range spans from a high of $75 to a low of $0.82. Over the trailing twelve-month period, shares declined 97.64%.Technical indicators showed MEDS trading with an RSI reading of 56.10 at reporting time.AGPU shares advanced 2.74% during the same session.Complete transaction documentation will be disclosed through a Current Report on Form 8-K submitted to the SEC.The post DataMEDS AI (MEDS) Stock Soars 87% Following Helomics Cancer Lab Acquisition appeared first on Blockonomi.